Search

BACKGROUND: Screening for islet autoantibodies in children and adolescents identifies individuals who will later develop type 1 diabetes, allowing patient and family education to prevent diabetic ketoacidosis at onset and to enable consideration of preventive therapies. We aimed to assess whether islet autoantibody screening is effective for predicting type 1 diabetes in adolescents aged 10−18 years with an increased risk of developing type 1 diabetes. METHODS: Data were harmonised from prospective studies from Finland (the Diabetes Prediction and Prevention study), Germany (the BABYDIAB study), and the USA (Diabetes Autoimmunity Study in the Young and the Diabetes Evaluation in Washington study). Autoantibodies against insulin, glutamic acid decarboxylase, and insulinoma-associated protein 2 were measured at each follow-up visit. Children who were lost to follow-up or diagnosed with type 1 diabetes before 10 years of age were excluded. Inverse probability censoring weighting was used to include data from remaining participants. Sensitivity and the positive predictive value of these autoantibodies, tested at one or two ages, to predict type 1 diabetes by the age of 18 years were the main outcomes. FINDINGS: Of 20 303 children with an increased type 1 diabetes risk, 8682 were included for the analysis with inverse probability censoring weighting. 1890 were followed up to 18 years of age or developed type 1 diabetes between the ages of 10 years and 18 years, and their median follow-up was 18·3 years (IQR 14·5–20·3). 442 (23·4%) of 1890 adolescents were positive for at least one islet autoantibody, and 262 (13·9%) developed type 1 diabetes. Time from seroconversion to diabetes diagnosis increased by 0·64 years (95% CI 0·34–0·95) for each 1-year increment of diagnosis age (Pearson’s correlation coefficient 0·88, 95% CI 0·50–0·97, p=0·0020). The median interval between the last prediagnostic sample and diagnosis was 0·3 years (IQR 0·1–1·3) in the 227 participants who were autoantibody positive and 6·8 years (1·6–9·9) for the 35 who were autoantibody negative. Single screening at the age of 10 years was 90% (95% CI 86–95) sensitive, with a positive predictive value of 66% (60–72) for clinical diabetes. Screening at two ages (10 years and 14 years) increased sensitivity to 93% (95% CI 89–97) but lowered the positive predictive value to 55% (49–60). INTERPRETATION: Screening of adolescents at risk for type 1 diabetes only once at 10 years of age for islet autoantibodies was highly effective to detect type 1 diabetes by the age of 18 years, which in turn could enable prevention of diabetic ketoacidosis and participation in secondary prevention trials. FUNDING: JDRF International.

AIMS/HYPOTHESES: Physical inactivity may contribute to islet autoimmunity and progression to clinical type 1 diabetes. To test this hypothesis, we evaluated physical activity, assessed by accelerometer, as an independent risk factor for progression to clinical diabetes among genetically at risk for type 1 diabetes children and youth with islet autoimmunity. METHODS: Accelerometer data were obtained for 95 children and youth participating in the Diabetes Autoimmunity Study in the Young who had islet autoimmunity. Islet autoimmunity was defined as the presence of islet autoantibodies to insulin, glutamic acid decarboxylase, tyrosine phosphatase-like protein IA-2, or zinc transporter 8. RESULTS: During prospective follow-up for up to 7 years, 13 of the 95 participants progressed to clinical diabetes. In multivariable survival analysis, none of the physical activity parameters examined predicted a higher risk of developing diabetes. In survival analysis with time-varying physical activity parameters, none of the physical activity parameters over time were associated with the risk of developing type 1 diabetes. CONCLUSIONS/INTERPRETATION: It does not appear that low physical activity is a risk factor for progression from islet autoantibodies to diabetes in children and youth at high genetic risk for type 1 diabetes.

OBJECTIVE Children identified with stage 1 type 1 diabetes are at high risk for progressing to stage 3 (clinical) diabetes and require accurate monitoring. Our aim was to establish continuous glucose monitoring (CGM) metrics that could predict imminent progression to diabetes. RESEARCH DESIGN AND METHODS In the Autoimmunity Screening for Kids study, 91 children who were persistently islet autoantibody positive (median age 11.5 years; 48% non-Hispanic White; 57% female) with a baseline CGM were followed for development of diabetes for a median of 6 (range 0.2–34) months. Of these, 16 (18%) progressed to clinical diabetes in a median of 4.5 (range 0.4–29) months. RESULTS Compared with children who did not progress to clinical diabetes (nonprogressors), those who did (progressors) had significantly higher average sensor glucose levels (119 vs. 105 mg/dL, P < 0.001) and increased glycemic variability (SD 27 vs. 16, coefficient of variation, 21 vs. 15, mean of daily differences 24 vs. 16, and mean amplitude of glycemic excursions 43 vs. 26, all P < 0.001). For progressors, 21% of the time was spent with glucose levels >140 mg/dL (TA140) and 8% of time >160 mg/dL, compared with 3% and 1%, respectively, for nonprogressors. In survival analyses, the risk of progression to diabetes in 1 year was 80% in those with TA140 >10%; in contrast, it was only 5% in the other participants. Performance of prediction by receiver operating curve analyses showed area under the curve of ≥0.89 for both individual and combined CGM metric models. CONCLUSIONS TA140 >10% is associated with a high risk of progression to clinical diabetes within the next year in autoantibody-positive children. CGM should be included in the ongoing monitoring of high-risk children and could be used as potential entry criterion for prevention trials.

Pancreas size, as measured by MRI, is smaller at the onset of T1D and in individuals at risk for T1D. To determine whether pancreas MRI predicts T1D progression, we measured pancreas size and shape longitudinally in Type 1 Diabetes TrialNet Pathway to Prevention study participants. To increase enrollment and expand this study across multiple TrialNet sites, we established the Multicenter Assessment of the Pancreas in T1D (MAP-T1D) group to develop harmonized MRI acquisition and image processing protocols and ensure the consistency of imaging results across sites. Using this standardized protocol (PMID: 34428220) , we performed longitudinal pancreas MRI in 41 multiple autoantibody-positive individuals (mean age y.o., range 8 - 45 y.o., 49% female) at three TrialNet Clinical Centers. Average time between study entry and diabetes diagnosis for individuals who progressed to Stage 3 was 54 months while non-progressors were followed for a median time of 63 months. Five study participants who developed Stage 3 T1D during follow up had a smaller pancreas (29.5 ± 9.0 ml vs. 54.8 ± 22.5 ml, p = 0.02) and smaller pancreas volume normalized by body weight (0.61 ± 0.18 ml/kg vs. 0.85 ± 0.23 ml, p = 0.03) at study entry compared with those who did not progress to Stage 3. We found that pancreas volume was stable over time, with no significant increase or decrease up to four years after the initial MRI (total of 123 MRIs) . There was no significant change in pancreas size in the five individuals who progressed to Stage 3 T1D. The shape of the pancreas at study onset was also different in the five individuals who progressed to Stage 3 T1D compared with non-progressors, with larger surface area to volume ratio (p = 0.02) , and shorter principal axes (p = 0.05, shortest axis; p = 0.02, second shortest axis) . These data suggest that small pancreas size and altered shape predicts progression from Stage 2 to Stage 3 T1D. Disclosure J.Virostko: None. L.H.Philipson: Advisory Panel; Nevro Corp., Research Support; Dompé, Novo Nordisk, provention BIo. T.Kay: None. H.E.Thomas: Research Support; Captix Biomedical, CSL Limited, Pandion Therapeutics, Procyon Technologies. S.W.Greeley: None. A.Steck: None. A.C.Powers: None. D.J.Moore: None. J.J.Wright: None. J.M.Williams: None. M.A.Hilmes: None. T.M.Triolo: None. H.C.Broncucia: None. L.Du: None. H.Kang: None. W.E.Russell: None. Funding NIDDK (R03DK129979, U24DK097771, UC4 DK106993, DK020593) ; JDRF International (3-SRA-2015-102-M-B, 3-SRA-2019-759-M-B) ; Thomas J. Beatson, Jr. Foundation (2021-003)

Viral infections may trigger islet autoimmunity leading to type 1 diabetes (T1D) . We hypothesized SARS-CoV-2 infection is associated with presence of islet autoantibodies (IAb) in children. Between 8/2020 and 12/2021, ASK screened 47general population Colorado children aged 1-17 y for IAb to GAD, insulin, IA-2 and ZnT8 as well as antibodies to SARS-CoV-2 receptor binding domain (CoV-2 RBDAb) - a sensitive and specific marker of infection. Of those, 4172 (89%) have not previously received SARS-CoV-2 vaccine. During the study period, prevalence of CoV-2 RBDAb increased in unvaccinated from 1% to 58% and up to 100% among vaccinated. Among all children, the prevalence increased from 1% to 72% - an estimate of herd immunity (Figure) . Among the unvaccinated, prevalence of multiple or single high-affinity IAb did not differ between children positive vs. negative for CoV-2 RBDAb, respectively 1.23% (16/1297) vs. 1.00% (29/2875) , p=0.52. In multivariate logistic regression, presence of IAb was not associated with presence of CoV-2 RBDAb (OR=1.40, p=0.31) , adjusting for age, sex, race/ethnicity, and family history of T1D. While we found no association between past SARS-CoV-2 infection and islet autoimmunity, a confirmation in a larger population is warranted. Longer follow-up will help assess whether SARS-CoV2 infection accelerates progression from islet autoimmunity to diabetes. Disclosure C.Geno rasmussen: None. X.Jia: None. H.Shorrosh: None. L.Yu: None. B.I.Frohnert: Advisory Panel; Provention Bio, Inc. K.M.Simmons: Advisory Panel; Provention Bio, Inc., Consultant; Dexcom, Inc. A.Steck: None. L.Pyle: None. M.Rewers: Consultant; Janssen Research & Development, LLC, Medscape, Provention Bio, Inc., Research Support; Dexcom, Inc., JDRF, Roche Diagnostics USA. Funding JDRF 2-SRA-2021-1065-M-N

In type 1 diabetes (T1D) , T cells target and destroy pancreatic beta cells. T cells express T cell receptors (TCRs) which recognize peptide antigens, and each TCR is unique to a given T cell. To understand the TCR repertoire during T1D development, we used next generation sequencing to detect TCRβ chains from longitudinal peripheral blood DNA samples at four time points from genetically at-risk cases (n=29) who progressed to T1D and age/sex/HLA matched controls (n=25) beginning early in life (median age 1.4 years) in the Diabetes Autoimmunity Study in the Young (DAISY) . Over 50 million TCRβ chains were sequenced, and the repertoires became less diverse (i.e., more clonal) over time with age in both groups (p Disclosure A.M.Mitchell: None. M.Nakayama: None. A.W.Michels: Employee; ImmunoMolecular Therapeutics, Stock/Shareholder; ImmunoMolecular Therapeutics. E.E.Baschal: None. K.Mcdaniel: None. L.Pyle: None. K.Waugh: None. A.Steck: None. L.Yu: None. P.Gottlieb: Advisory Panel; Janssen Research & Development, LLC, ViaCyte, Inc., Other Relationship; IM Therapeutics, Research Support; Caladrius Biosciences, Inc., Immune Tolerance Network, National Institute of Diabetes and Digestive and Kidney Diseases, Novo Nordisk, Precigen, Inc., Tolerion, Inc. M.Rewers: Consultant; Janssen Research & Development, LLC, Medscape, Provention Bio, Inc., Research Support; Dexcom, Inc., JDRF, Roche Diagnostics USA. Funding National Institutes of Health (DK108868, DK110845, DK032083, DK032493, DK116073) Juvenile Diabetes Research Foundation (3-PDF-2020-943-A-N) Leona M. & Harry B. Helmsley Charitable Trust (2103-05093) Colorado Clinical and Translational Science Institute (TR002535)

Modeling the course of C-peptide decline in autoantibody (Ab) positive individuals is important for type 1 diabetes (T1D) prediction and implementation of T1D prevention trials. Single nucleotide polymorphisms in TCF7L2, JAZF1, SLC30A8, INS, PTPRK, G6CP2, CLEC16, PTPN22 and HLA genes are associated with persistent C-peptide at or after T1D diagnosis. We sought to determine whether 12 SNPs in these genes and the T1D genetic risk score-2 (GRS2) can predict C-peptide trajectory before diagnosis of T1D. We studied Ab positive at-risk participants in the TrialNet Pathway to Prevention Study who had ImmunoChip data (N=1217, age at initial screen (mean±SD) 16.1±12.7 years, 51.5% female, 81.0% non-Hispanic white) . Over a mean follow up of 3.4±2. years, 255 (21.0%) developed multiple Ab and 336 (27.6%) developed clinical T1D. We analyzed the influence of these 12 SNPs and the T1D GRS2 on C-peptide AUC during progression from single to multiple Abs, from single Ab to clinical T1D, and from multiple Abs to clinical T1D. Analyses were adjusted for baseline C-peptide AUC, age, glucose AUC, BMI Z-score and HbA1c; the presence of high-risk HLA haplotypes (DR3 and DR4-DQ8) ; and the first 3 principal components. The type 2 diabetes (T2D) -associated TCF7L2 rs7901695 and rs4506565 SNPs were significantly associated with higher C-peptide AUC during progression from multiple Abs to T1D (p In conclusion, T2D-associated SNPs in the TCF7L2 gene and lower T1D GRS2 predict higher C-peptide particularly in progression from multiple Abs to clinical T1D. Disclosure T.M.Triolo: None. M.J.Redondo: Advisory Panel; Provention Bio, Inc. H.M.Parikh: None. M.Tosur: Advisory Panel; Provention Bio, Inc. P.Gottlieb: Advisory Panel; Janssen Research & Development, LLC, ViaCyte, Inc., Other Relationship; IM Therapeutics, Research Support; Caladrius Biosciences, Inc., Immune Tolerance Network, National Institute of Diabetes and Digestive and Kidney Diseases, Novo Nordisk, Precigen, Inc., Tolerion, Inc. R.A.Oram: Consultant; Janssen Research & Development, LLC, Research Support; Randox R & D. S.Onengut-gumuscu: None. J.Krischer: None. S.S.Rich: None. A.Steck: None. Funding NIH K12 DK094712NIH RDK121843NIH RDK124395

The complete 1H and 13C NMR data of 27 pravastatin derivatives are presented. Assignment was achieved by use of 1D and 2D NMR experiments (selective 1D NOE, COSY, NOESY, HSQC, HMBC). Copyright © 2008 John Wiley & Sons, Ltd.

BACKGROUND & AIMS: It is not clear how intake of gluten during infancy affects subsequent risk of celiac disease. We investigated whether gluten intake before 2 years of age increases risk for celiac disease in genetically susceptible children. METHODS: We performed a case-control study of 436 pairs of children, generated from a database of 2525 children with genetic susceptibility to celiac disease in Sweden, matched for sex, birth year, and HLA genotype from September 2004 and February 2010. Children were screened annually for celiac disease using an assay for tissue transglutaminase autoantibodies (tTGA). Intestinal biopsies were collected from children who tested positive for tTGA to confirm the presence of celiac disease. Gluten intake was calculated from 3-day food records collected when the children were 9, 12, 18 and 24 months old. RESULTS: Breastfeeding duration (median 32 weeks) and age at first introduction to gluten (median 22 weeks) did not differ between cases and tTGA-negative children (controls). At the visit prior to tTGA seroconversion, cases reported a larger intake of gluten (median 4.9 g/day) than controls (median 3.9 g/day) (odds ratio [OR], 1.28; 95% confidence interval [CI], 1.13-1.46; P=.0002). More cases consumed amounts of gluten in the upper 3rd tertile (i.e. >5.0 g/day) before they tested positive for tTGA seroconversion than controls (OR, 2.65; 95% CI, 1.70-4.13; P

A thorough product analysis of the reaction of ascomycin with diazomethane has been performed. Apart from the expected oxiranes (epimeric at C9), a whole range of novel derivatives bearing various modifications in the binding domain were obtained. Proposed mechanisms for their formation and stereochemical aspects are discussed.

6-Vinyl ( 12 ) and (5R)- and (5S)-vinylproline ( 18 , 19 ) analogues of ascomycin are synthesised starting from the known suitably protected (6S)-methoxy-9-hydroxy derivative ( 4 ) of ascomycin. The strategy involves hydrolytic cleavage of the Ce–N bond of the pipecolic acid moiety, extension of the amino acid side chain by two or one carbon units, functional group manipulations, Pd-catalysed reinstallation of the Ce–N or Cδ–N bonds, followed by deprotection and oxidation.

The natural product ascomycin represents a highly functionalised 23-membered macrocycle with a polyketide backbone. Within the binding domain, ascomycin features the unusual pattern of a masked tricarbonyl moiety, which potentially allows for high structural diversity via simple isomerisation events. Herein, highly stereoselective, hydroxide mediated rearrangement reactions at the binding domain are reported.

Violaxanthin A (=(all-E,3S,5S,6R,3′S,5′S,6′R)-5,6 : 5′,6′-diepoxy-5,6,5′,6′-tetrahydro-β,β-carotene-3,3′-diol =syn,syn-violaxanthin; 5) and violaxanthin B (=(all-E,3S,5S,6R,3′S,5′R,6′S)-5,6 : 5′,6′-diepoxy-5,6,5′,6′-tetrahydro-β,β-carotene-3,3′-diol=syn,anti-violaxanthin; 6) were prepared by epoxidation of zeaxanthin diacetate (1) with monoperphthalic acid. Violaxanthins 5 and 6 were submitted to thermal isomerization and I2-catalyzed photoisomerization. The structure of the main products, i.e., (9Z)-5, (13Z)-5, (9Z)-6, (9′Z)-6, (13Z)-6, and (13′Z)-6, was determined by their UV/VIS, CD, 1H-NMR, 13C-NMR, and mass spectra.

Within the binding domain, ascomycin features the unusual pattern of a masked tricarbonyl moiety, which potentially allows for high structural diversity via simple isomerisation events. Herein, methodologies, allowing the liberation of the tricarbonyl unit by blocking the 14-hydroxy group are reported.

A two-step protocol for the first chemoselective cleavage of 2-hydroxy acid amides has been developed. Mesylation of the model substrate 2-(hydroxypropionylamino)-4-methylpentanoic acid methyl ester (11) followed by treatment with N-ethylthiourea (13) allows cleavage of 2-hydroxy acid amides under smooth conditions. Successful application of this methodology to the open-chain transesterification product 15 (methylester) of the cyclic heptadepsipeptide HUN-7293, a potent inhibitor of inducible cell adhesion molecule expression, delivered the corresponding hexapeptide 18 with unprotected N-terminus in 70-75% yield. This result demonstrates that the protocol developed even works in the presence of an ester and several methylated and unmethylated amide bonds. Finally, a sequence of ligation of methyl D-dehydroglutaminate (20) to the C-terminus of the saponification product 21, followed by the degradation protocol and ring closure, allowed chemical "point mutation" at the DGCN site affording the aza analogue of HUN-7293 (24) in 15% overall yield. To the best of our knowledge this is the first report on chemoselective cleavage of 2-hydroxy acid amides.

Structure elucidation of 9-S and 9-R oxirane derivatives of ascomycin, a 23-membered immunomodulating macrolactam, was performed using NMR spectroscopy. The total 1H and 13C signal assignments required the gradient-selected versions of COSY (gs-COSY), heteronuclear multiple quantum-correlation spectroscopy (gs-HSQC), heteronuclear multiple-bond correlation spectroscopy (gs-HMBC), and nuclear Overhauser methods. The data sets then were used to examine the dependence of ketone–hemiketal and cis–trans amide equilibria on the substitution pattern and the absolute configuration of the chiral oxirane. Copyright © 2002 John Wiley & Sons, Ltd.

To examine the current extent of the obesity problem in 2 large pediatric clinical registries in the US and Europe and to examine the hypotheses that increased body mass index (BMI) z-scores (BMIz) are associated with greater hemoglobin A1c (HbA1c) and increased frequency of severe hypoglycemia in youth with type 1 diabetes (T1D).International (World Health Organization) and national (Centers for Disease Control and Prevention/German Health Interview and Examination Survey for Children and Adolescents) BMI references were used to calculate BMIz in participants (age 2-18 years and ≥ 1 year duration of T1D) enrolled in the T1D Exchange (n = 11,435) and the Diabetes Prospective Follow-up (n = 21,501). Associations between BMIz and HbA1c and severe hypoglycemia were assessed.Participants in both registries had median BMI values that were greater than international and their respective national reference values. BMIz was significantly greater in the T1D Exchange vs the Diabetes Prospective Follow-up (P.001). After stratification by age-group, no differences in BMI between registries existed for children 2-5 years, but differences were confirmed for 6- to 9-, 10- to 13-, and 14- to 17-year age groups (all P.001). Greater BMIz were significantly related to greater HbA1c levels and more frequent occurrence of severe hypoglycemia across the registries, although these associations may not be clinically relevant.Excessive weight is a common problem in children with T1D in Germany and Austria and, especially, in the US. Our data suggest that obesity contributes to the challenges in achieving optimal glycemic control in children and adolescents with T1D.

Starting from 33- O -silyl-protected ascomycin or its 23,24-dehydration product, regio- and stereo-selective formal aldol reactions under carbon–carbon bond formation at C-22, C-23, or C-24 are demonstrated. Additionally, with the 22-silyl enol ether ascomycin derivative a rhodium(I)-catalysed shift of the 19,20 double bond into the 19,38 exocyclic position is observed at elevated temperature.

(13Z,13'Z,3R,3'R,6'R)-Lutein has been isolated and purified from extracts of marigold flowers, fresh raw kale (Brassica oleracea var. Acephala), and human plasma and fully characterized by (1)H and (13)C NMR, UV/vis, and MS. While the concentration of (13Z, 13'Z)-lutein in kale and human plasma compared to (all-E,3R,3'R, 6'R)-lutein was found to be quite low, this compound was readily isolated by fractional crystallization of lutein from marigold extracts. Thus, the mother liquors from two consecutive crystallizations of lutein from a saponified extract of marigold flowers were enriched in (13Z,13'Z)-lutein (8.7% of total carotenoids) and employed for the isolation of this compound by HPLC. The identity of the di-Z-lutein in kale and human plasma has been established by comparison of the HPLC-UV/vis-MS profiles of the purified compounds with those of a fully characterized sample, isolated from marigolds. 3-Hydroxy-beta,epsilon-caroten-3'-one and 3'-epilutein have also been identified in extracts from marigolds.

Sixteen carotenoids were isolated from the flesh of Brazilian red guavas (Psidium guajava L.). Their structures were established by means of UV−visible, 400 and 500 MHz 1H NMR, 120 and 125 MHz 13C NMR, mass, and circular dichroism spectra. The carotenoids were identified as phytofluene, (all-E)-, (9Z)-, (13Z)-, and (15Z)-β-carotene, (all-E)-γ-carotene, (all-E)-, (9Z)-, (13Z)-, and (15Z)-lycopene, (all-E,3R)-β-cryptoxanthin, (all-E,3R)-rubixanthin, (all-E,3S,5R,8S)-cryptoflavin, (all-E,3R,3‘R,6‘R)-lutein, (all-E,3S,5R,6R,3‘S,5‘R,8‘R)-, and (all-E,3S,5R,6R,3‘S,5‘R,8‘S)-neochrome. Thirteen of the carotenoids identified are reported as guava carotenoids for the first time. Keywords: Carotenoids; isolation; LC/MS; NMR; guava; Psidium guajava L.

Two oxidative metabolites of lycopene in tomato paste, tomato juice, and human serum have been prepared by partial synthesis from oxidation of lycopene with m-chloroperbenzoic acid (MCPBA) followed by acidic hydrolysis. Extensive 1H and 13C NMR spectroscopy studies of the purified products of these reactions have confirmed that the major oxidation products of lycopene (I) are lycopene 1,2-epoxide (II) and lycopene 5,6-epoxide (III) (tentative assignment). Several diepoxides of lycopene, namely, lycopene 1,2;5,6-diepoxide (IV), lycopene 1,2;5‘,6‘-diepoxide (V), lycopene 5,6;5‘,6‘-diepoxide (VI), and lycopene 1,2;1‘,2‘-diepoxide (VII), which were formed as minor products, were tentatively identified. Whereas lycopene 1,2-epoxide was found to be fairly stable, lycopene 5,6-epoxide underwent cyclization to form a mixture of diastereomeric epoxides A (VIII, major) and B (IX, minor). The trivial names of 2,6-cyclolycopene-1,5-epoxides A (VIII) and B (IX) have been assigned to these compounds with a novel five-m...

Reinvestigation by HPLC of the petals ofLilium tigrinum and the isolation of some minor compounds is reported. Using HPLC-controlled, preparative-column chromatography, 5,6-diakarpoxanthin (6), 6-epikarpoxanthin (2), 5,6-diacapsokarpoxanthin (8), and 9Z-antheraxanthin (9Z-13) were isolated and characterized. Based on spectroscopic data the absolute configurations of6 and8 were identical with those originating from paprika, thus the 5,6-diakarpoxanthin (6) and 5,6-diacapsokarpoxanthin (8) have the 3S, 5S, 6S configuration and 6-epikarpoxanthin (2) has the 3S, 5R, 6S configuration.

The acid-catalyzed hydrolysis of (3S,5R,6S,3′S,5′R)-5,6-epoxycapsanthin (5) led to (3S,5R,6R,3′S,5′R)-(7) and (3S,5R,6S,3′S,5′R)-capsokarpoxanthin (8). In addition, (3S,5R,8R,3′S,5′R)- (9), (3S,5R,8S,3′S,5′R)-capsochrome (10), and (3S,5R,6R,3′S,5′R)-3,6-epoxycapsanthin (6) afforded (3S,5S,6R,3′S,5′R)-capsokarpoxanthin (12) (3S,5S,8S,3′S,5′R)- (13) and (3S,5S,8R,3′S,5′S)-capsochrome (14) as well as (3S,5S,6R,3′S,5′R)-3,6-epoxyepicapsanthin (15). Compounds 5–15 were isolated in crystalline form and characterized by their UV/VIS, CD, 1H- and 13C-NMR, and mass spectra.

6-Epikarpoxanthin ((all-E,3S,5R,6S,3′R)-5,-6-dihydro-β,β-carotene-3,5,6,3′-tetrol, 5), 5,6-diepikarpoxanthin ((all-E,3S,5S,6S,3′R)-5,6-β,β-carotene-3,5,6,3′-tetrol, 13), 5,6-diepilatoxanthin ((all-E,3S,5S,6S,3′S5′R,6′S)-5,6′-epoxy-5,6,5′,6′-tetrahydro-β,β-carotene-3,5,6,3′-tetrol, 14), and 5,6-diepicapsokarpoxanthin ((all-E,3S,5S,6S,3′S,5′R)-5,6-dihydro-3,5,6,3′-tetrahydroxy-β,κ-caroten-6′-one, 15) were isolated from red spice paprika (Capsicum annuum var. longum) and characterized by their UV/VIS, CD, 1H- and 13C-NMR, and mass spectra. Our investigations demonstrate that the configuration of the 3,5,6-trihydroxy-5,6-dihydro-β-end group may differ depending on the biological source.

Dihydrooxepin derivatives 1 and 2 were obtained by oxidation of canthaxanthin with m-CPBA and of β,β-carotene with molecular oxygen, respectively.

β-Cryptoxanthin (1) was acetylated and then epoxidized with monoperoxyphthalic acid. After hydrolysis, repeated chromatography, and crystallization, (3S,5R,6S)-5,6-epoxy-β-cryptoxanthin (3), (3S,5S,6R)-5,6-epoxy-β-cryptoxanthin (4), (3R,5′R,6′R)-5′,6′-epoxy-β-cryptoxanthin (5), (3S,5R,6S,5′R,6′S)-5,6:5′,6′-diepoxy-β-cryp-toxanthin (6), and (3S,5S,6R,5′S,6′R)-5,6:5′,6′-diepoxy-β-cryptoxanthin (7) were isolated as main products and characterized by their UV/VIS, CD, 1H- and 13C-NMR, and mass spectra. The comparison of the carotenoid isolated from yellow, tomato-shaped paprika (Capsicum annuum var. lycopersiciforme flavum) with 3–5 strongly supports the structure of 3 for the natural product.

Optimizing glycemic control in pediatric type 1 diabetes (T1D) is essential to minimizing long-term risk of complications. We used the T1D Exchange database from 58 US diabetes clinics to identify differences in diabetes management characteristics among children categorized as having excellent vs. poor glycemic control.Among registry participants 6-17 yr old with diabetes duration ≥ 2 yr, those with excellent control [(A1c7%)(53 mmol/mol) (N = 588)] were compared with those with poor control [(A1c ≥ 9% )(75 mmol/mol) (N = 2684)] using logistic regression.The excellent and poor control groups differed substantially in diabetes management (p0.001 for all) with more of the excellent control group using insulin pumps, performing blood glucose monitoring ≥ 5 ×/d, missing fewer boluses, bolusing before meals rather than at the time of or after a meal, using meal-specific insulin:carbohydrate ratios, checking their blood glucose prior to giving meal time insulin, giving insulin for daytime snacks, giving more bolus insulin, and using a lower mean total daily insulin dose than those in poor control. After adjusting for demographic and socioeconomic factors, diabetes management characteristics were still strongly associated with good vs. poor control. Notably, frequency of severe hypoglycemia was similar between the groups while DKA was more common in the poorly controlled group.Children with excellent glycemic control tend to exhibit markedly different diabetes self-management techniques than those with poor control. This knowledge may further inform diabetes care providers and patients about specific characteristics and behaviors that can be augmented to potentially improve glycemic control.

Isomerization of (all-E)-Cycloviolaxanthin. Preparation and Characterization of (9Z)- and (13Z)-Cycloviolaxanthin From (all-E)-cycloviolaxanthin (ex Capsicum annuum), (9Z)- and (13Z)-cycloviolaxanthin were prepared in a highly pure state. The configuration of both isomers was determined by means of UV/VIS, NMR, and CD spectroscopy.

Cucurbitaxanthin A (= (3S,5R,6R,3′R)-3,6-epoxy-5,6-dihydro-β,β- carotene-5,3′-diol; 5), cucurbitaxanthin B (= (3S,5R,6R,3′S,5′R,6′S)-3,6,5′, 6′-diepoxy-5,6,5′,6′-tetrahydro-β,β-carotene-5,3′-diol; 6), the epimeric cucurbitachromes 1 and 2 (= (3S,5R,6R,3′S,5′R,8′S)- and (3S,5R,6R,3′S,5′R,8′R)-3,6,5′, 8′-diepoxy-5,6,5′,6′-tetrahydro-β,β-carotene-5,3′-diol, resp.; 9/10), cycloviolaxanthin (= (3S,5R,6R,3′S,5′R,6′R)-3,6,3′, 6′-diepoxy-5,6,5′,6′-tetrahydro-β,κs-carotene-5,5′-diol; 8), and capsanthin 3,6-epoxide (= (3S,5R,6R,3′S,5′R)-3,6-epoxy-5,6-dihydro −5,3′-dihydroxy-β,κ-caroten-6′-one; 7) were isolated from red spice paprika (Capsicum annuum var. longum) and characterized by their 1H- and 13C-NMR, mass, and CD spectra.

Within the binding domain, ascomycin features the unusual pattern of a masked tricarbonyl moiety, which potentially allows for high structural diversity via simple isomerisation events. A cascade of diastereoselective rearrangement reactions at the binding domain, allowing the conversion of ascomycin into 11- epi -ascomycin is herein reported.

6-Epikarpoxanthin ((all-E,3S,5R,6S,3′R)-5,-6-dihydro-β,β-carotene-3,5,6,3′-tetrol, 5), 5,6-diepikarpoxanthin ((all-E,3S,5S,6S,3′R)-5,6-β,β-carotene-3,5,6,3′-tetrol, 13), 5,6-diepilatoxanthin ((all-E,3S,5S,6S,3′S5′R,6′S)-5,6′-epoxy-5,6,5′,6′-tetrahydro-β,β-carotene-3,5,6,3′-tetrol, 14), and 5,6-diepicapsokarpoxanthin ((all-E,3S,5S,6S,3′S,5′R)-5,6-dihydro-3,5,6,3′-tetrahydroxy-β,κ-caroten-6′-one, 15) were isolated from red spice paprika (Capsicum annuum var. longum) and characterized by their UV/VIS, CD, 1H- and 13C-NMR, and mass spectra. Our investigations demonstrate that the configuration of the 3,5,6-trihydroxy-5,6-dihydro-β-end group may differ depending on the biological source.

The acid-catalyzed hydrolysis of (3S,5R,6S,3′S,5′R)-5,6-epoxycapsanthin (5) led to (3S,5R,6R,3′S,5′R)-(7) and (3S,5R,6S,3′S,5′R)-capsokarpoxanthin (8). In addition, (3S,5R,8R,3′S,5′R)- (9), (3S,5R,8S,3′S,5′R)-capsochrome (10), and (3S,5R,6R,3′S,5′R)-3,6-epoxycapsanthin (6) afforded (3S,5S,6R,3′S,5′R)-capsokarpoxanthin (12) (3S,5S,8S,3′S,5′R)- (13) and (3S,5S,8R,3′S,5′S)-capsochrome (14) as well as (3S,5S,6R,3′S,5′R)-3,6-epoxyepicapsanthin (15). Compounds 5–15 were isolated in crystalline form and characterized by their UV/VIS, CD, 1H- and 13C-NMR, and mass spectra.

The complete (1)H and (13)C NMR data of 27 pravastatin derivatives are presented. Assignment was achieved by use of 1D and 2D NMR experiments (selective 1D NOE, COSY, NOESY, HSQC, HMBC).

The cyclic depsipeptide HUN-7293 (1) and its D-lactate analogue 2 are highly potent inhibitors of inducible cell adhesion molecule expression. We report the synthesis of ether analogues varying in stereochemistry and side chain at the former hydroxyl acid position by employing a 'cut and paste chemistry' methodology starting from 1. As an additional fruit of this synthetic effort, a cyclodepsipeptide featuring a tertiary amine instead of a tertiary amide between PrLEU and MALA was obtained. Results on the inhibitory profile of these compounds in assays of VCAM-1 and ICAM-1 protein expression are discussed.

Common fruits and vegetables contain approximately 40 to 50 carotenoids. Carotenoid-containing fruits and vegetables can be classified into three groups: greens, yellow/red, and yellow/orange. The carotenoids present in greens comprise carotenoid epoxides, lutein, α-carotene, and β-carotene. The yellow/red group contains mostly hydrocarbon carotenoids such as lycopene, neurosporene, y-carotene, ζ-carotene, a-carotene, β-carotene, phytofluene, and phytoene. Yellow/orange fruits and vegetables, in addition to the carotenoids in the other two categories, contain a complex mixture of carotenoids including carotenol fatty acid esters. The effect of various methods of food preparation on qualitative and quantitative distribution of carotenoids in common fruits and vegetables is described. An approach to selection of a mixture of carotenoids as chemopreventive agents based on absorption and relative abundance of these compounds in human serum is discussed.

Lutein and lycopene are among the most abundant dietary carotenoids found in fruits, vegetables, and human serum. Human absorption and bioavailability studies involving lutein and its structural isomer zeaxanthin have established in vivo oxidation of these carotenoids to four metabolites. Lycopene apparently undergoes oxidation to yield lycopene-5,6-epoxide followed by cyclization and enzymatic reduction to form two dihydroxylycopenes with a novel five-member ring end-group. These dihydroxylycopenes, which have been identified as epimeric isomers of 2,6-cyclolycopene-1,5-diol, have been found in human serum. We present here our most recent data concerning the identity of 24 carotenoids, including eight of their metabolites in human serum. Possible metabolic transformations and the antioxidant mechanism of action for lutein and lycopene that lead to the formation of the oxidative metabolites of these two promising chemopreventive agents are described.

From different species of paprika (Capsicum annuum) capsanthone (1) was isolated and characterized as (all-E,3R,5'R)-3-hydroxy-β,κ-carotene-3',6'-dione.

From red paprika (Capsicum annuum var. longum nigrum) nigroxanthin (1) was isolated as a minor carotenoid and, based on its spectral data, identified as (all-E)-3',4'-didehydro-β,γ-carotene-3,6'-diol.